Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
letter
. 2020 Jun 3;312:136. doi: 10.1016/j.ijcard.2020.04.066

COVID-19 and cardiovascular injury: A role for oxidative stress and antioxidant treatment?

Lorenzo Loffredo 1,, Francesco Violi 1
PMCID: PMC7833193  PMID: 32505331

To the Editor,

The coronavirus disease 2019 (COVID-19), seems to have a cardiovascular tropism characterized by high incidence of myocardial infarction especially for patients with severe infections recovered in intensive care units. In their letter, the Authors state that oxidative stress could play a pivotal role to determine cardiovascular complications in COVID-19. We agree about this issue. In particular, NADPH oxidase-2 (NOX-2), that it is considered one of the most important sources of superoxide anion in human [1], plays a role in systemic inflammation and pathogenesis of several RNA virus as the influenza virus [2]. Furthermore, NOX-2 is increased in patients with pneumonia and is closely associated with troponin elevation, suggesting that the activation of this enzyme could elicit the myocardial damage [3]. Thus, it could be possible to argue that COVID-19 is associated with Nox-2-derived oxidative stress but data regarding this issue are still lacking.

The question is: how to reduce oxidative stress and improve the poor outcome that characterized severe COVID-19?

Vitamin C could represent a plausible approach as it is able to scavenge reactive oxidant species and reduces Nox-2 activation when intravenously infused [4]. However, the use of vitamin C in ARDS or sepsis is still a matter of debate as data at this regard are discordant [5]. Thus, future studies should explore the clinical efficacy of antioxidants in COVID-19.

Financial disclosure

All the authors have no financial relationships to disclose relevant to this article.

Declaration of competing interest

All the authors have no conflicts of interest to disclose.

References

  • 1.Violi F., Carnevale R., Loffredo L., Pignatelli P., Gallin J.I. NADPH oxidase-2 and atherothrombosis: insight from chronic granulomatous disease. Arterioscler. Thromb. Vasc. Biol. 2017;37:218–225. doi: 10.1161/ATVBAHA.116.308351. [DOI] [PubMed] [Google Scholar]
  • 2.To EE, Vlahos R., Luong R., Halls M.L., Reading P.C., King P.T. Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy. Nat. Commun. 2017;8:69. doi: 10.1038/s41467-017-00057-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Violi F., Carnevale R., Calvieri C., Nocella C., Falcone M., Farcomeni A. Nox2 up-regulation is associated with an enhanced risk of atrial fibrillation in patients with pneumonia. Thorax. 2015;70:961–966. doi: 10.1136/thoraxjnl-2015-207178. [DOI] [PubMed] [Google Scholar]
  • 4.Violi F., Pastori D., Pignatelli P., Loffredo L. Antioxidants for prevention of atrial fibrillation: a potentially useful future therapeutic approach? A review of the literature and meta-analysis. Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology. 2014;16:1107–1116. doi: 10.1093/europace/euu040. [DOI] [PubMed] [Google Scholar]
  • 5.Obi J., Pastores S.M., Ramanathan L.V., Yang J., Halpern N.A. Treating sepsis with vitamin C, thiamine, and hydrocortisone: exploring the quest for the magic elixir. J. Crit. Care. 2020 doi: 10.1016/j.jcrc.2019.12.011. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from International Journal of Cardiology are provided here courtesy of Elsevier

RESOURCES